All In Biotech

Drug Trial Radar · NCT01423500

ALL-SCT BFM International- HSCT in Children and Adolescents With ALL

Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia

Last checked: Nov 20, 2026Latest source record: Jun 26, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

405

Planned (sponsor's estimate)

Start

Jan 2007

Primary completion

Sep 2011

Study completion Sep 2016

Sponsor

Lead sponsor
St. Anna KinderkrebsforschungAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 26, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 3 months, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

With this protocol the ALL-SCT BFM international study group wants * to evaluate whether hematopoietic stem cell transplantation (HSCT) from matched family or unrelated donors (MD) is equivalent to the HSCT from matched sibling donors (MSD). * to evaluate the efficacy of hematopoietic stem cell transplantation (HSCT)from mismatched family or unrelated donors (MMD) as compared to HSCT from matched sibling donors or matched donors. * to determine whether therapy has been carried out according to the main HSCT protocol recommendations. The standardisation of the treatment options during HSCT from different donor types aims at the achievement of an optimal comparison of survival after HSCT with survival after chemotherapy only. * to prospectively evaluate and compare the incidence of acute and chronic Graft-versus-Host-Disease (GvHD) after HSCT from matched sibling donor (MSD), from matched donor (MD) and from mismatched donor (MMD).

Conditions

  • Lymphoblastic Leukemia, Acute, Childhood;

Interventions

  • VP16Drug

    patients with MSD receive as conditioning VP16 60mg/kg/d on day -3

  • TBIRadiation

    patients with a MSD receive TBI (12Gy in 6 fractions) as conditioning

  • VP16, ATGDrug

    patients with a HLA matched unrelated Donor (9/10 oder 10/10) receive VP16 60mg/kg/d on day -3 and ATG fresenius 20mg/kg/d on day -3,-2,-1

  • TBIRadiation

    patients with a HLA matched unrelated Donor (9/10 oder 10/10) receive TBI (12Gy in 6 fractions)

  • Fludarabine, OKT3, Treosulfan, ThiotepaDrug

    patients with a MMD (haploidentical or cord blood) receive Fludarabine 30mg/m²/d on day -9 to -5, ATG fresenius 20mg/kg/d on day -3,-2,-1, Treosulfan 14g/m²/d on day -7 to -5 and Thiotepa 2x5mg/kg/d on day -4

  • VP16, ATGDrug

    patients with MMD-transplantation (8/10)receive VP16 60mg/kg/d on day -4, ATG from day -3 to day-1 20mg/kg/d

  • TBIRadiation

    patients with a MMD-transplantation (8/10) receive 12 Gy in 6 fractions

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Event free survivalTime frame: 10 years

Locations

24 sites in 11 countries. Site status is shown where the registry gives one.

  • Universitätsklinik für Kinder- und Jugendheilkunde, Klin. Abt. f. Hämato-Onkologie

    Graz, Austria

  • Universitätsklinik für Kinder- und Jugendheilkunde

    Innsbruck, Austria

  • St. Anna Children's Hospital

    Vienna, Austria

  • Department of Paediatric Haematology and Oncology HSCT-Unit

    Prague, Czechia

  • Pediatric Clinic II, Rigshospitalet

    Copenhagen, Denmark

  • Pediatric Immuno-Hematology Unit Robert Debré Hospital

    Paris, France

  • Rambam Medical Center

    Haifa, Israel

  • Schneider Children's Medical Center of Israel

    Petah Tikva, Israel

  • Clinica Pediatrica dell'Universita di Milano Bicocca, Hospitale San Gerardo

    Monza, Italy

  • Leiden University Hospital

    Leiden, Netherlands

  • Radboud University - Nijmegen Medical Centre

    Nijmegen, Netherlands

  • Department of Paediatric Haematology and Oncology, Wilhelmina Children's Hospital

    Utrecht, Netherlands

  • University Hospital, Collegium Medicum UMK, Pediatric Hematology and Oncology

    Bydgoszcz, Poland

  • Department of Transplantation, University Children's Hospital

    Cracow, Poland

  • Children's University Hospital - Hematology - Oncology

    Lublin, Poland

  • Department of Pediadric Oncology, Hematology and Transplantology, University of Medical Sciences

    Poznan, Poland

  • Wroclaw Medical University, Dept. of Children Hematology and Oncology

    Wroclaw, Poland

  • Department of Pediatric Bone Marrow Transplantation Unit, University Childrens´ Hospital

    Bratislava, Slovakia

  • Department of Pediatric Oncology, Lund University Hospital

    Lund, Sweden

  • Department of Pediatrics, Gülhane Military Medical Academy

    Ankara, Turkey (Türkiye)

  • Dept. of Paediatrics - BMT Unit, School of Medicine, University of Ankara

    Ankara, Turkey (Türkiye)

  • Department of Pediatric Hematology-Oncology and Pediatric Stem Cell Transplantation, Akdeniz University School of Medicine

    Antalya, Turkey (Türkiye)

  • Department of Pediatric Hematology, Oncology and BMT, Istanbul School of Medicine

    Istanbul, Turkey (Türkiye)

  • Pediatric BMT Centre, Ege University

    Izmir, Turkey (Türkiye)

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.